Home Sectors Healthcare Stock in the Spotlight: Emergent Biosolutions (NYSE: EBS)

Stock in the Spotlight: Emergent Biosolutions (NYSE: EBS)


Emergent Biosolutions is part of the healthcare sector and biotechnology industry. The company CEO is Daniel J. Abdun-Nabi. Emergent BioSolutions Inc is a biotechnology company operating in two divisions: biodefense and biosciences. The company focuses on countermeasures that address public health threats around hematology and oncology therapeutics.

Previous Intraday Trading Performance:

The EBS stock showed a previous change of -8.58% with an open at 55.92 and a close of 52.09. It reached an intraday high of 56.19 and a low of 51.34.

SeekingAlpha:  Emergent Bio nabs federal contract valued as high as $100M


The stock has a market cap of $2.7b with 51.2m shares outstanding, of which the float is 48.9m shares. Trading volume reached 1,300,608 shares compared to its average volume of 439,265 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Emergent Biosolutions shares returned -8.73% and in the past 30 trading days it returned -13.96%. Over three months, it changed -21.44%. In one year it has changed -0.84% and within that year its 52-week high was 73.89 and its 52-week low was 46.93. EBS stock is 11.00% above its 52 Week Low.

Our calculations show a 200 day moving average of 60.13 and a 50 day moving average of 61.28. Currently EBS stock is trading -13.38% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

SeekingAlpha:  Emergent Biosolutions: Leader In The Public Health Threats Space


The last annual fiscal EPS for the company was reported at 2.34 that ended on 31st of December 2018, which according to the previous close, that is a PE of 42.70. Based on 3 analyst estimates, the consensus EPS for the next quarter is 0.61. The TTM EPS is 2.34, which comes to a TTM PE of 22.26. Historically, the PE high was 49.00 and the PE low was 19.40. If the stock reached its PE low, that would represent a price of 45.40, which is a decrease of -12.85%.

The following are the last four quarter reported earnings per share:
12-31-2018:  0.75
09-30-2018:  0.55
06-30-2018:  1.07
03-31-2018:  -0.03

Base on our calculations, the intrinsic value per share is 58.87, which means it is possibly undervalued and has a margin of safety of 11.51%

Indicators to Watch:

Based on the latest filings, there is 129.20% of institutional ownership. Short-interest is 3,049,314, which is 5.96% of shares outstanding. The short-interest ratio or days-to-cover ratio is 8.52. This stock has a moderate level of short interest, but may still be a buying opportunity depending on other indicators.

The current calculated beta is 1.36

SeekingAlpha:  Emergent Biosolutions: Leader In The Public Health Threats Space

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is 6.66%, return on assets is 3.85%, profit margin is 8.16%, price-to-sales is 3.73 and price-to-book is 2.89.

Company Scores:

All scores are out of six:
 1  :Valuation Score
 1  :Past Performance Score
 2  :Financial Strength Score
 2  :Future Growth Score
 0  :Dividend Score
 1  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.